Matrx’s SĀPH™ provide superior stability and improved release kinetics for the delivery of standard oncotherapies for the treatment of solid tumors including doxorubicin, taxol, and cis-platinum as well as new immune- and/or protein-based therapies.
Matrx’s SĀPH™ delivers both large and small molecules, providing improved targeting and controlled delivery, maintaining therapeutic levels at the site of delivery resulting in reduced application, dosing and negative side effects resulting interaction with non-target cells. Localized delivery of drugs is further enhanced using Matrx’s tailorable platform, the surfaces of which can be modified for improved binding and residence with specific tissue types. Drugs can be embedded within the SĀPH™ matrix, which provides reservoirs for both hydrophobic and hydrophilic compounds, or conjugated directly to the base peptide to affect delivery and uptake. Unlike typical sustained delivery matrices, the unique properties of SĀPH™ promote drug-mediated crosslinking of the the delivery matrix, enhancing stability and increasing achievable delivery times.